Nuvation Bio Inc. (NUVB) shareholders
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Hung, M.D | 61,269,498 | 27.70% | 13D (active) amendment | Mar 24, 2024 |
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 50,599,225 | 15.00% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (13.50%) | 45,285,572 | 13.50% | 13G (passive) amendment | Dec 31, 2024 |
| Xiangmin Cui Joint filing with Decheng Anbio Limited (5.20%) | 26,600,496 | 8.00% | 13D (active) | Sep 3, 2024 |
| BlackRock, Inc. | 21,708,843 | 6.40% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NUVB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 52,230,295 | 14.88% | $296.67M | +240,702 | 0.01% |
| BlackRock, Inc. | 27,630,837 | 7.87% | $156.94M | +2,530,463 | 0.00% |
| Decheng Capital LLC | 25,954,439 | 7.39% | $147.42M | – | 20.15% |
| Vanguard Capital Management LLC | 11,919,514 | 3.39% | $67.70M | +293,316 | 0.00% |
| Omega Fund Management, LLC | 8,081,089 | 2.30% | $45.90M | – | 24.72% |
| Laurion Capital Management LP | 7,820,013 | 2.23% | $44.42M | −2,625 | 1.14% |
| State Street Corp | 7,370,794 | 2.10% | $41.87M | +585,867 | 0.00% |
| Geode Capital Management, LLC | 6,244,805 | 1.78% | $35.48M | +381,151 | 0.00% |
| Duquesne Family Office LLC | 4,539,800 | 1.29% | $25.79M | – | 0.49% |
| American Century Companies Inc | 4,499,643 | 1.28% | $25.56M | +1,602,565 | 0.01% |
| Bank Of America Corp /De/ | 3,529,748 | 1.01% | $20.05M | +309,922 | 0.00% |
| Tang Capital Management LLC | 3,299,557 | 0.94% | $18.74M | +150,000 | 0.85% |
| Redmile Group, LLC | 3,031,009 | 0.86% | $17.22M | −122,247 | 1.16% |
| Vanguard Portfolio Management LLC | 2,688,666 | 0.77% | $15.27M | +413,220 | 0.00% |
| Aqr Capital Management LLC | 2,356,429 | 0.67% | $13.38M | +360,671 | 0.00% |
| Northern Trust Corp | 2,321,873 | 0.66% | $13.19M | +318,765 | 0.00% |
| Algert Global LLC | 2,277,358 | 0.65% | $12.94M | +435,280 | 0.15% |
| Hrt Financial LP | 2,207,779 | 0.63% | $12.54M | New | 0.00% |
| Charles Schwab Investment Management Inc | 2,058,870 | 0.59% | $11.69M | +66,419 | 0.00% |
| Dimensional Fund Advisors LP | 2,047,876 | 0.58% | $11.63M | −4,815 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 244 | 233M | 66.5% | 40 / 111 | 52 / 25 | 24M | 10M |
| Q1 2026 | 233 | 221M | 62.8% | 48 / 91 | 59 / 37 | 46M | 21M |
| Q4 2025 | 224 | 212M | 60.3% | 56 / 72 | 70 / 33 | 24M | 34M |
| Q3 2025 | 203 | 221M | 63.0% | 40 / 83 | 48 / 17 | 22M | 26M |
| Q2 2025 | 182 | 225M | 64.1% | 43 / 79 | 31 / 20 | 27M | 10M |
| Q1 2025 | 161 | 207M | 59.1% | 23 / 54 | 52 / 19 | 21M | 9M |
| Q4 2024 | 160 | 198M | 56.3% | 29 / 64 | 36 / 22 | 41M | 29M |
| Q3 2024 | 154 | 188M | 53.4% | 26 / 60 | 36 / 18 | 59M | 8M |
| Q2 2024 | 148 | 153M | 43.6% | 42 / 46 | 39 / 17 | 27M | 11M |
| Q1 2024 | 124 | 137M | 39.0% | 27 / 42 | 38 / 17 | 13M | 11M |
| Q4 2023 | 116 | 135M | 38.5% | 14 / 44 | 32 / 23 | 18M | 19M |
| Q3 2023 | 125 | 137M | 39.0% | 13 / 50 | 36 / 12 | 10M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
177 funds held NUVB in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NUVB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 17,536,601 | 4.99% | $83.82M | 0.08% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,849,329 | 2.52% | $50.26M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,570,059 | 1.87% | $37.32M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 4,910,563 | 1.40% | $23.47M | 0.09% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 4,516,478 | 1.29% | $21.59M | 0.09% | May 31, 2026 |
| Small Cap Growth Fund | 3,423,823 | 0.98% | $21.67M | 0.39% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,787,909 | 0.79% | $15.84M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,755,576 | 0.78% | $17.44M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,326,568 | 0.66% | $13.21M | 0.09% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,758,533 | 0.50% | $8.41M | 0.16% | May 31, 2026 |
| iShares Biotechnology ETF | 1,743,392 | 0.50% | $9.90M | 0.11% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 1,427,463 | 0.41% | $8.11M | 1.89% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,239,034 | 0.35% | $5.92M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,238,081 | 0.35% | $5.92M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,145,077 | 0.33% | $5.47M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Hung | PRESIDENT AND CEO, Director, 10% owner | 59,281,054 | 16.88% | Mar 3, 2026 |
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | 0 | – | Aug 21, 2026 |
| Philippe Sauvage | Chief Financial Officer | 54,130 | 0.02% | Jul 17, 2026 |
| Stacy Markel | CHIEF PEOPLE OFFICER | 157,591 | 0.04% | Jun 24, 2026 |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | 116,000 | 0.03% | Jun 24, 2026 |
| Dongfang Liu | CHIEF MEDICAL OFFICER | 68,000 | 0.02% | Apr 21, 2026 |
| Colleen Sjogren | Chief Commercial Officer | 84,000 | 0.02% | Mar 3, 2026 |
| David C. Hanley | CHIEF TECHNICAL OPERATIONS | 24,000 | 0.01% | Mar 3, 2026 |
| Moses Makunje | SEE REMARKS | 68,137 | 0.02% | Mar 3, 2026 |
| Robert Mashal | Director | 225,000 | 0.06% | Jun 11, 2026 |
| Xiangmin Cui | Director | 25,954,439 | 7.39% | May 26, 2026 |
| Robert B. Bazemore | Director | 5,000 | 0.00% | May 26, 2026 |
| W. Anthony Vernon | Director | 254,100 | 0.07% | May 26, 2026 |
| Kathryn E. Falberg | Director | 250,000 | 0.07% | May 26, 2026 |
| Kim D. Blickenstaff | Director | 172,189 | 0.05% | May 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Aug 19, 2026 | Sale(10b5-1 plan) | −100,000 | $7.09 | $709.00K | 0 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Aug 19, 2026 | Option exercise | +100,000 | $1.87 | $187.00K | 100,000 |
| Philippe Sauvage Chief Financial Officer | Jul 15, 2026 | Option exercise | +39,999 | $2.17 | $86.80K | 54,130 |
| Philippe Sauvage Chief Financial Officer | Jul 15, 2026 | Option exercise | +1 | $1.97 | $2 | 54,131 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 23, 2026 | Option exercise | +63,000 | $2.93 | $184.59K | 116,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 23, 2026 | Sale(10b5-1 plan) | −63,000 | $6.02 | $379.26K | 53,000 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 23, 2026 | Option exercise | +34,620 | $1.74 | $60.24K | 157,591 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 23, 2026 | Sale(10b5-1 plan) | −125,000 | $6.03 | $753.75K | 32,591 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 23, 2026 | Option exercise | +90,380 | $1.87 | $169.01K | 122,971 |
| Philippe Sauvage Chief Financial Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −47,668 | $6.01 | $286.48K | 12,673 |
| Philippe Sauvage Chief Financial Officer | Jun 23, 2026 | Option exercise | +47,668 | $2.17 | $103.44K | 60,341 |
| Robert Mashal Director | Jun 9, 2026 | Buy | +25,000 | $4.73 | $118.25K | 225,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −36,750 | $5.01 | $184.12K | 53,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 17, 2026 | Option exercise | +36,750 | $2.93 | $107.68K | 89,750 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Apr 17, 2026 | Option exercise | +50,000 | $1.94 | $97.00K | 68,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −50,000 | $5.02 | $251.00K | 18,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 6, 2026 | Option exercise | +100,000 | $1.87 | $187.00K | 153,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 6, 2026 | Option exercise | +100,000 | $1.94 | $194.00K | 253,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Apr 6, 2026 | Sale(10b5-1 plan) | −200,000 | $4.52 | $904.00K | 53,000 |
| Moses Makunje SEE REMARKS | Feb 27, 2026 | Award | +50,761 | – | – | 68,137 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Dec 1, 2025 | Sale | −150,000 | $7.82 | $1.17M | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Dec 1, 2025 | Option exercise | +150,000 | $2.93 | $439.50K | 168,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 26, 2025 | Option exercise | +10,000 | $3.61 | $36.10K | 28,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 26, 2025 | Sale | −10,000 | $8.00 | $80.00K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 25, 2025 | Option exercise | +10,000 | $3.61 | $36.10K | 28,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 25, 2025 | Sale | −10,000 | $7.50 | $75.00K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 20, 2025 | Sale | −20,000 | $7.00 | $140.00K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 20, 2025 | Option exercise | +20,000 | $1.87 | $37.40K | 38,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Sale | −300,000 | $7.23 | $2.17M | 0 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Option exercise | +300,000 | $1.94 | $582.00K | 300,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Sale | −69,051 | $7.23 | $499.24K | 0 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Nov 20, 2025 | Option exercise | +69,051 | $1.74 | $120.15K | 69,051 |
| David C. Hanley CHIEF TECHNICAL OPERATIONS | Nov 19, 2025 | Sale | −200,000 | $7.14 | $1.43M | 24,000 |
| David C. Hanley CHIEF TECHNICAL OPERATIONS | Nov 19, 2025 | Option exercise | +200,000 | $1.87 | $374.00K | 224,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 19, 2025 | Sale | −15,000 | $5.10 | $76.50K | 18,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 19, 2025 | Option exercise | +15,000 | $1.87 | $28.05K | 30,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 17, 2025 | Sale | −15,000 | $4.77 | $71.55K | 15,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | Nov 17, 2025 | Option exercise | +15,000 | $1.87 | $28.05K | 30,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Oct 27, 2025 | Option exercise | +100,000 | $1.74 | $174.00K | 100,000 |
| Gary Hattersley CHIEF SCIENTIFIC OFFICER | Oct 27, 2025 | Sale(10b5-1 plan) | −100,000 | $5.02 | $502.00K | 0 |
| Stacy Markel CHIEF PEOPLE OFFICER | Jun 18, 2025 | Buy | +10,000 | $1.71 | $17.10K | 29,591 |
| Philippe Sauvage Chief Financial Officer | Jun 17, 2025 | Buy | +4,000 | $1.79 | $7.16K | 9,902 |
| Philippe Sauvage Chief Financial Officer | Jun 16, 2025 | Buy | +3,300 | $1.84 | $6.07K | 5,902 |
| David Hung PRESIDENT AND CEO, Director, 10% owner | Jun 16, 2025 | Buy | +500,000 | $1.79 | $895.00K | 59,281,054 |
| Colleen Sjogren Chief Commercial Officer | Jun 16, 2025 | Buy | +50,000 | $1.81 | $90.50K | 81,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 16, 2025 | Buy | +26,000 | $1.79 | $46.54K | 26,000 |
| Kerry Wentworth CHIEF REGULATORY OFFICER | Jun 16, 2025 | Buy | +24,000 | $1.80 | $43.20K | 50,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | May 2, 2025 | Option exercise | +20,000 | $1.94 | $38.80K | 32,000 |
| Dongfang Liu CHIEF MEDICAL OFFICER | May 2, 2025 | Sale(10b5-1 plan) | −20,000 | $2.50 | $50.00K | 12,000 |
| David Hung PRESIDENT AND CEO, Director, 10% owner | Apr 7, 2025 | Buy | +300,000 | $1.63 | $489.00K | 58,781,054 |
| David Hung PRESIDENT AND CEO, Director, 10% owner | Apr 4, 2025 | Buy | +200,000 | $1.66 | $332.00K | 58,481,054 |
| Robert Mashal Director | Apr 1, 2025 | Buy | +1,100 | $1.67 | $1.84K | 101,100 |
| Robert Mashal Director | Apr 1, 2025 | Buy | +98,900 | $1.67 | $165.16K | 200,000 |
| Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD., Director | Nov 11, 2024 | Sale | −56,361 | $2.89 | $162.88K | 3,866,228 |
| Robert Mashal Director | Oct 8, 2024 | Buy | +99,981 | $2.20 | $219.96K | 100,000 |
| Robert Mashal Director | Oct 8, 2024 | Buy | +19 | $2.20 | $42 | 19 |
| Xiangmin Cui Director | Sep 4, 2024 | Conversion | +5,157,900 | – | – | 7,611,031 |
| Xiangmin Cui Director | Sep 4, 2024 | Conversion | +967,100 | – | – | 1,281,206 |
| Xiangmin Cui Director | Sep 4, 2024 | Conversion | +12,879,200 | – | – | 17,062,202 |
| Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD., Director | Sep 4, 2024 | Conversion | +2,543,600 | – | – | 3,922,589 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nuvation Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 782,277 shares on Sep 23, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Gary Hattersley Officer | Aug 19, 2026 | 100,000 | $696.00K | Aug 19, 2026 | Exercise of Stock Options |
| Stacy Markel Officer | Jun 23, 2026 | 125,000 | $720.00K | Jun 23, 2026 | Exercise of Stock Options |
| Kerry Wentworth Officer | Jun 23, 2026 | 63,000 | $362.88K | Jun 23, 2026 | Exercise of Stock Options |
| Philippe Sauvage Officer | Jun 23, 2026 | 47,668 | $274.57K | Jun 23, 2026 | Exercise of Stock Options |
| Kerry Wentworth Officer | Apr 17, 2026 | 36,750 | $176.77K | Apr 17, 2026 | Exercise of Stock Options |
| Dongfang Liu Officer | Apr 17, 2026 | 50,000 | $240.50K | Apr 17, 2026 | Exercise of Stock Options |
| Kerry Wentworth Officer | Apr 6, 2026 | 200,000 | $882.00K | Apr 6, 2026 | Exercise of Stock Options |
| Dongfang Liu Officer | Dec 1, 2025 | 150,000 | $1.17M | Dec 1, 2025 | Exercise of options under a registered plan |
| Dongfang Liu Officer | Nov 26, 2025 | 10,000 | $80.00K | Nov 26, 2025 | Exercise of options under a registered plan |
| Dongfang Liu Officer | Nov 25, 2025 | 10,000 | $75.00K | Nov 25, 2025 | Exercise of options under a registered plan |
| Dongfang Liu Officer | Nov 20, 2025 | 20,000 | $140.07K | Nov 20, 2025 | Exercise of options under a registered plan |
| Gary Hattersley Officer | Nov 20, 2025 | 369,051 | $2.67M | Nov 20, 2025 | Exercise of options under a registered plan |
| Dongfang Liu Officer | Nov 19, 2025 | 15,000 | $76.55K | Nov 19, 2025 | Exercise of options under a registered plan |
| David C. Hanley Officer | Nov 19, 2025 | 200,000 | $1.43M | Nov 19, 2025 | Exercise of options under a registered plan |
| Dongfang Liu Officer | Nov 17, 2025 | 15,000 | $71.48K | Nov 17, 2025 | Exercise of options under a registered plan |
See a number that looks wrong?